Jordan Cabinet approves document to secure Pfizer medication for 8,000 COVID-19 patients

Cabinet on Thursday endorsed draft amendments to a law restructuring public institutions and departments for 2022

  
Medical staff members wearing protective gear walk along a section for patients suffering from the coronavirus disease (COVID-19), inside a hospital in Amman, Jordan March 23, 2021. Picture taken March 23, 2021. Image used for illustrative purpose.

Medical staff members wearing protective gear walk along a section for patients suffering from the coronavirus disease (COVID-19), inside a hospital in Amman, Jordan March 23, 2021. Picture taken March 23, 2021. Image used for illustrative purpose.

REUTERS/Muath Freij

AMMAN- The Cabinet on Thursday endorsed draft amendments to a law restructuring public institutions and departments for 2022.

The draft amendments follow a Royal Decree to establish the Ministry of Investment in a bid to realise an investment friendly environment and find suitable solutions for challenges and obstacles facing this sector, the Jordan News Agency, Petra, reported.

Under the amendments, the tasks and authorities of the Investment Commission will be referred to the ministry.

Meanwhile, the Council of Ministers approved the first condition document to secure COVID-19 medication for 8,000 patients as part of an agreement between the Health Ministry and US pharmaceutical company Pfizer.

The Cabinet also approved appointing Maher Al Mahrouq, director general of the Association of Banks in Jordan, as member of the board of directors of the Jordan Postal Saving Fund, and Mohammed Raggad as member of the board of directors of the Jordan Radio and Television Corporation.

© Copyright The Jordan Times. All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Levant